The renin-angiotensin and the kallikrein-kinin systems

被引:106
作者
Campbell, DJ
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
关键词
angiotensin; bradykinin; kallidin; kallikrein; kininogen; kallistatin;
D O I
10.1016/S1357-2725(02)00262-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS) each encompasses a large number of molecules, with several participating in both systems. The RAS generates a family of bioactive angiotensin peptides with varying biological activities. These include angiotensin-(1-8) (An-II), angiotensin-(2-8) (Ang III), angiotensin-(3-8) (Ang IV), and angiotensin-(1-7) [Ang-(1 -7)]. An-II and Ang III act on type 1 (AT(1)) and type 2 (AT(2)) angiotensin receptors, whereas, Ang IV and Ang-(1-7) act on their own receptors. The KKS also generates a family of bioactive peptides with varying biological activities. These include hydroxylated and non-hydroxylated bradykinin and kallidin peptides and their carboxypeptidase metabolites des-Arg(9)-bradykinin and des-Arg(10)-kallidin. Whereas bradykinin and kallidin act mainly viathe type 2 bradykinin (B-2) receptor, des-Arg(9)-bradykinin and des-Arg(10)-kallidin act mainly via the type 1 bradykinin (B-1) receptor. The AT(1) receptor forms heterodimers with the AT(2) and B-2 receptors and there is cross talk between the AT(1) and epidermal growth factor receptors. The B-2 receptor also interacts with angiotensin converting enzyme and nitric oxide synthase. Both angiotensin and kinin peptides are metabolised by many different peptidases that are important determinants of the activities of the RAS and KKS, and several of which participate in both systems. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 32 条
[1]   The angiotensin II AT2 receptor is an AT1 receptor antagonist [J].
AbdAlla, S ;
Lother, H ;
Abdel-tawab, AM ;
Quitterer, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (43) :39721-39726
[2]   AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration [J].
AbdAlla, S ;
Lother, H ;
Quitterer, U .
NATURE, 2000, 407 (6800) :94-98
[3]   Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness [J].
AbdAlla, S ;
Lother, H ;
el Massiery, A ;
Quitterer, U .
NATURE MEDICINE, 2001, 7 (09) :1003-1009
[4]   Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase [J].
Albiston, AL ;
McDowall, SG ;
Matsacos, D ;
Sim, P ;
Clune, E ;
Mustafa, T ;
Lee, J ;
Mendelsohn, FAO ;
Simpson, RJ ;
Connolly, LM ;
Chai, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48623-48626
[5]  
Armstrong Paul W, 2002, Circulation, V106, pe9011
[6]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[7]   The kallikrein-kinin system in humans [J].
Campbell, DJ .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (12) :1060-1065
[8]  
CAMPBELL DJ, 2001, ANGIOTENSIN 2 RECEPT, P9
[9]   Angiotensinogen and its cleaved derivatives inhibit angiogenesis [J].
Célérier, J ;
Cruz, A ;
Lamandé, N ;
Gase, JM ;
Corvol, P .
HYPERTENSION, 2002, 39 (02) :224-228
[10]  
Duncan AM, 1999, J PHARMACOL EXP THER, V289, P295